Adults with type 2 diabetes assigned tirzepatide alongside insulin glargine had greater reductions in HbA1c and body weight compared with placebo, according to data from the SURPASS trial program. In findings from the SURPASS-5 randomized clinical trial published in JAMA, participants assigned 5 mg, 10 mg or 15 mg tirzepatide (Eli Lilly), a glucose-dependent insulinotropic polypeptide
Combo GIP/GLP-1 Injectable Beats Insulin for A1c Reduction medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Spanish minister Pedro Duque details reforms in science and innovation: Spain will be an entrepreneurial country businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.